CA Patent

CA2446738C — Abuse-resistant opioid dosage form

Assigned to Endo Pharmaceuticals Inc · Expires 2012-05-29 · 14y expired

What this patent protects

The present invention pertains to a pharmaceutical dosage from comprising an opioid agonist and one or more opioid antagonists contained in a matrix separate from the opioid agonist. The separate matrix for the opioid antagonist allows independent release rates to be achieved for…

USPTO Abstract

The present invention pertains to a pharmaceutical dosage from comprising an opioid agonist and one or more opioid antagonists contained in a matrix separate from the opioid agonist. The separate matrix for the opioid antagonist allows independent release rates to be achieved for the opioid and opioid antagonist(s). The antagonist(s) can be released slowly or fully contained when the tablet is taken orally. Crushing the tablet allows full release of the antagonist(s), deterring abuse. The abuse deterring antagonist(s) may be an opioid antagonist, an irritant, another appropriate antagonist(s), or a combination thereof. The invention also allows variable release of the opioid and antagonist(s).

Drugs covered by this patent

Patent Metadata

Patent number
CA2446738C
Jurisdiction
CA
Classification
—
Expires
2012-05-29
Drug substance claim
No
Drug product claim
No
Assignee
Endo Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.